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Abstract
Aging and gender have a strong influence on the functional capacity of the immune system. In general, the immune
response in females is stronger than that in males, but there is scant information about the effect of aging on the gender
difference in the immune response. To address this question, we performed a transcriptomic analysis of peripheral blood
mononuclear cells derived from elderly individuals (nonagenarians, n = 146) and young controls (aged 19–30 years, n = 30).
When compared to young controls, we found 339 and 248 genes that were differentially expressed (p,0.05, fold change
.1.5 or ,21.5) in nonagenarian females and males, respectively, 180 of these genes were changed in both genders. An
analysis of the affected signaling pathways revealed a clear gender bias: there were 48 pathways that were significantly
changed in females, while only 29 were changed in males. There were 24 pathways that were shared between both
genders. Our results indicate that female nonagenarians have weaker T cell defenses and a more prominent pro-
inflammatory response as compared to males. In males significantly fewer pathways were affected, two of which are known
to be regulated by estrogen. These data show that the effects of aging on the human immune system are significantly
different in males and females.
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Introduction
Old age is associated with a higher risk of inflammatory
diseases, autoimmune disorders and malignancies. This increased
risk is due to the decreased function of the immune system, with
immunosenescence and chronic low-grade inflammation, termed
inflamm-aging, representing the key changes [1]. With advancing
age, the number of naı¨ve CD4+ and CD8+ T cells declines, while
the number of memory and effector cells increases. One
prominent feature of old age is the increased proportion of late-
stage differentiated CD8+ T cell clones that lack the expression of
the costimulatory molecule CD28. Additionally, T cell function is
modulated with advancing age; older individuals show a restricted
T cell receptor (TCR) repertoire and defects in TCR-mediated
signaling [2]. Similar to T cells, the number of naı¨ve B cells is
decreased, while the number of memory B cells is increased [3].
Inflamm-aging is another hallmark of aging. In the elderly, the
blood levels of pro-inflammatory cytokines (IL-6, TNF-a and
CRP) are increased, but the cellular sources and inductive signals
underlying this expression are still largely unknown [4].
The immune system shows strong sexual dimorphism. Gener-
ally, females are more immunocompetent, meaning that they show
increased resilience to various infections and some non-infectious
diseases, such as cancer [5]. However, as a result, females are more
prone to autoimmune disorders. Sex hormones are correlated with
some of these differences, but other physical, and possibly social,
factors may have a role in the sexual dimorphism of immune
functions [5], [6]. In general, females and males age differently, as
most clearly observed in the variance of morbidity and mortality
rates between the genders [7]. However, the combined effects of
aging and gender on the human immune system have not been
analyzed previously.
Results
To better understand the combinatorial effects of age and
gender on the immune system, we analyzed the global gene
expression profile of peripheral blood mononuclear cells (PBMCs)
from nonagenarians (n = 146, 103 females, 43 males) and young
controls (n = 30, aged 19–30 years, 21 females, 9 males) using an
Illumina Human HT12v4 BeadChip array. The data were
analyzed with the Chipster program [8] (IT Center for Science
Ltd (CSC), Espoo, Finland). Using a cut-off of p,0.05 and a fold
change (FC) of below 21.5 or above 1.5, we identified 339 genes
that were differentially expressed in female nonagenarians
compared to female controls, and 248 genes that were differen-
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tially expressed in male nonagenarians compared to male controls.
Of these genes, 180 were common to both genders (Figure 1). The
top 10 up- and down-regulated genes are shown in Table 1, and
all differentially expressed genes are listed in Tables S1 and S2.
The expression levels of four transcripts were verified with qPCR.
The transcripts verified included both up- and down-regulated
transcript as well as transcripts with high and low FC. The results
acquired through qPCR were positively correlated with the
microarray results. The expression of CD83, IL8 and LRRN3
were measured, with FCs (microarray/qPCR) in males of 1.73/
1.90, 3.46/7.26 and 24.68/25.65, respectively. In females, the
fold changes (microarray/qPCR) for CD83, IL8, LRRN3 and
PLCG1 were 1.70/1.71, 4.85/6.15, 25.64/27.81 and 21.63/
21.98, respectively.
To identify the biological pathways affected, Ingenuity Pathway
Analysis software (IPA) (IngenuityH Systems, www.ingenuity.com)
was used. Of the pathways by the Ingenuity Knowledge Base, our
analysis revealed 48 pathways that were significantly affected in
females (p,0.05, FDR,0.25 and at least 3 genes from the
pathway were up- or down-regulated) and 29 pathways that were
affected in males. Of these pathways, 24 were common to both
genders. B cell development was the most significantly affected
pathway in both genders. Other pathways that were significantly
affected included the Dendritic cell maturation pathway and T helper
cell differentiation pathway (Table 2, Table S3). Furthermore,
changes in a significant number of pathways were found to be
age-dependent in only one of the genders. In females, there were
24 gender-specific pathways (i.e. pathways that were only affected
in females), and the most significantly affected signaling pathway
was CTLA4 signaling in cytotoxic T lymphocytes. In males, there were
fewer gender-specific pathways (5 in total), and the Estrogen mediated
S-phase entry pathway was most affected (Tables 3 and 4). The
proportions of different T cell subpopulations in the study subjects
were determined with FACS analysis (Table S4) and no
statistically significant differences were found between the genders.
Thus, unequal representation of different T cell subsets can be
excluded as an explanation for these gender-specific differences.
Discussion
In summary, the data presented here suggests that the effect of
aging on the function of the human immune system is different
between males and females. Aging-associated changes in gene
expression have previously been studied in PBMCs [9], [10], but
these studies did not consider the effect of gender. Several genes
identified in our study have previously been associated with aging
or advanced age, including LEF1 [9], [10], [11], [12], VPREB3
[10], NR4A2 [11], LRRN3 [9], [10], [12], CCR7 [12], [13] and
CD19 [13]. All of these genes were affected in both genders. All of
the pathways that were found to be significantly affected by aging
in both genders of nonagenarians in this study have been reported
associated with aging in the literature. We also identified one novel
pathway, TREM1 signaling, that has not been previously associated
with aging. TREM1 signaling has a role in acute inflammation; it is
expressed in blood neutrophils and monocytes, and its expression
is induced by pathogens (LPS, bacteria and fungi [14], [15]). It
appears that the TREM1 signaling pathway contributes to the pro-
inflammatory state in elderly populations.
In addition to the pro-inflammatory pathways that are affected
in nonagenarians of both genders, several pro-inflammatory
pathways were affected only in females (Table 3). This result is
not surprising, because females generally to have stronger
inflammatory reactions [6]. One reason for the muted inflamma-
tory response in males may be testosterone, which is known to
have anti-inflammatory effects [16]. NF-kB signaling is affected in
both genders, but in females, there were more genes with this
pathway that were affected. In addition, two NO synthesis-
associated pathways were affected only in females, which indicates
more potent NF-kB signaling and an elevated pro-inflammatory
response in females because iNOS induction and NO synthesis are
induced by NF-kB and other pro-inflammatory cytokines [17].
The p38 MAPK signaling pathway, which was significantly affected
in females only, can also be activated by cell stressors other than
pro-inflammatory cytokines [18]. This result indicates that females
may have a more potent stress response than males.
Several of the age dependent, female-specific pathways are
involved in the activation of T lymphocytes (Table 3), suggesting
that gender may play an important regulatory role in T cell-
mediated defense. Because the expression levels of several genes in
these pathways were either up- or down regulated, it is difficult to
reconstruct the functional end result. However, because the
CTLA4 signaling in cytotoxic T lymphocytes pathway, including elevated
expression of CTLA4, and the iCOS-iCOSL signaling in T helper cells
pathway were significantly affected in females only, it appears that
the T cell-mediated defense is weaker in female nonagenarians
than in male nonagenarians.
Figure 1. Genes differentially expressed in nonagenarians. We
found 339 genes that were differentially expressed in female
nonagenarians, compared to young female controls, and 248 genes
that were differentially expressed in male nonagenarians, compared to
young male controls (p,0.05, 21.5. FC .1.5). A total of 180 of these
genes were common to both genders. Slightly more genes were up-
regulated (1b) than were down-regulated (1c) in the nonagenarians of
both genders.
doi:10.1371/journal.pone.0066229.g001
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The Cytotoxic T lymphocyte mediated apoptosis of target cells pathway
was also found to be affected by age in females only. Chronic viral
infections, e.g. cytomegalovirus (CMV) and Epstein-Barr virus,
affect a large majority of the nonagenarian population. In our
nonagenarian study population 96% of the females and 95% of
the males were seropositive for CMV. Cytotoxic CD8+ cells are
the primary cell type that controls these viral infections, but
chronic viral infections can also induce the generation of atypical
Table 1. Ten most up- and down-regulated genes found in females and males.
Gender Symbol Description p FC
Female LRRN3* leucine rich repeat neuronal 3 ,0.000001 25.639
CCR7 chemokine (C-C motif) receptor 7 ,0.000001 23.613
LOC652694 similar to Ig kappa chain V-I region HK102 precursor ,0.000001 22.877
IGJ immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu
polypeptides
,0.000001 22.848
CD27 CD27 molecule ,0.000001 22.747
CD79A CD79a molecule, immunoglobulin-associated alpha ,0.000001 22.680
CD19 CD19 molecule ,0.000001 22.651
IGLL1 immunoglobulin lambda-like polypeptide 1 ,0.000001 22.643
SGK223 homolog of rat pragma of Rnd2 ,0.000001 22.643
FCRLA Fc receptor-like A ,0.000001 22.628
IL8* interleukin 8 ,0.000001 4.851
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and
cyclooxygenase)
,0.000001 3.792
NR4A2 nuclear receptor subfamily 4, group A, member 2 ,0.000001 3.169
RHOB ras homolog gene family, member B ,0.000001 2.951
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) ,0.000001 2.909
IL1B interleukin 1, beta ,0.000001 2.840
RGS1 regulator of G-protein signaling 1 ,0.000001 2.766
EGR1 early growth response 1 ,0.000001 2.609
CCL3L3 chemokine (C-C motif) ligand 3-like 3 ,0.000001 2.600
HBEGF heparin-binding EGF-like growth factor ,0.000001 2.557
Male LRRN3* leucine rich repeat neuronal 3 ,0.000001 24.678
CD79A CD79a molecule, immunoglobulin-associated alpha 0.000034 23.073
CCR7 chemokine (C-C motif) receptor 7 ,0.000001 23.045
CD19 CD19 molecule 0.000005 22.963
FCRLA Fc receptor-like A 0.000010 22.874
CD79B* CD79b molecule, immunoglobulin-associated beta ,0.000001 22.713
NELL2 NEL-like 2 (chicken) ,0.000001 22.709
LOC652694 similar to Ig kappa chain V-I region HK102 precursor 0.000169 22.423
LEF1 lymphoid enhancer-binding factor 1 ,0.000001 22.414
VPREB3 pre-B lymphocyte 3 ,0.000001 22.413
IL8 interleukin 8 0.007899 3.459
NR4A2 nuclear receptor subfamily 4, group A, member 2 0.000001 3.422
JUN jun proto-oncogene 0.005935 3.046
RGS1 regulator of G-protein signaling 1 0.000015 2.935
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) ,0.000001 2.868
OSM oncostatin M 0.000784 2.716
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and
cyclooxygenase)
0.003393 2.684
HBEGF heparin-binding EGF-like growth factor 0.000422 2.615
IL1B interleukin 1, beta 0.005170 2.561
ADM adrenomedullin 0.000034 2.433
The 10 most down- and up-regulated transcripts in female and male nonagenarians compared to young controls. All differentially expressed transcripts are listed in
supplementary Tables S1 (males) and S2 (females).
*There are several transcripts of this gene, only the one with largest FC is shown.
doi:10.1371/journal.pone.0066229.t001
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cytotoxic CD4+ cells, which express granzyme B [19]. Because
chronic viral infections are thought to be a driving force behind
age-associated changes in the immune system, and because there is
no difference in seroprevalence between the genders, it is of great
interest to determine whether the immune systems of males and
females control these infections in different ways. Additionally, the
production of IL-15, a major homeostatic cytokine, was affected
only in females (the IL-15 production pathway). Previously, it was
shown that the blood levels of this cytokine are elevated in
centenarians [20], [21], but our data show that this phenomenon
is restricted to female nonagenarians, at least at the transcriptional
level (FC=1.6).
Significantly fewer pathways were affected in males than in
females (Table 4). Males also had fewer differentially expressed
transcripts, but this does not completely explain the difference in
the number of pathways, as the canonical pathway analysis in IPA
takes into account the number of input transcripts. The Estrogen
mediated S-phase entry pathway was most significantly changed.
Generally, estrogen is known to have an effect on inflammation,
and to possibly have a protective role against oxidative stress. The
Table 2. The canonical pathways that were most affected in nonagenarians of both genders.
Canonical pathway 2logFDR 2logP Ratio Rank Molecules
B Cell Development Females 6.04 8.40 0.276 1 PTPRCq, CD19Q, HLA-DOAQ, CD79BQ, HLA-DQA1q, CD86q, HLA-DOBQ,
CD79AQ
Males 5.43 7.86 0.241 1 PTPRCq, CD19Q, HLA-DOAQ, SPNq, CD79BQ,HLA-DOBQ,CD79AQ
B Cell Receptor Signaling Females 2.04 3.29 0.062 12 PTPRCq, CD19Q, JUNq, CD79BQ, FCGR2Aq, EGR1q, PIK3AP1q, CREB5q,
BCL6q, CD79AQ
Males 1.06 2.32 0.043 11 PTPRCq, CD19Q, JUNq, CD79BQ, EGR1q, BCL6q, CD79AQ
Communication between Innate
and Adaptive Immune Cells
Females 3.48 5.15 0.097 4 IL8q, TLR10Q, IL15q, CCL3L1/CCL3L3q, CD86q, IL1Bq, CD83q, CCL3q,
CCR7Q
Males 1.75 3.34 0.065 5 IL8q, TLR10Q, CCL3L1/CCL3L3q, IL1Bq, CD83q, CCR7Q
Crosstalk between Dendritic Cells
and Natural Killer Cells
Females 2.36 3.72 0.089 9 LTAQ, CD69q, IL15q, LTBQ, CD86q, CD83q, CCR7Q, FASq
Males 0.62 1.52 0.044 21 KIR3DL2q, LTBQ, CD83q, CCR7Q
Dendritic Cell Maturation Females 6.04 8.24 0.089 2 HLA-DOAQ, LEPq, FCGR2Aq, IL15q, HLA-DQA1q, PLCG1Q, LTBQ, CD83q,
CREB5q, FCGR1Aq, LTAQ, HLA-DOBQ, CD86q, IL1Bq, STAT1q, CCR7Q,
FCGR1Bq
Males 1.84 3.49 0.047 4 HLA-DOAQ, LTBQ, HLA-DOBQ, IL1Bq, CD83q, STAT1q, FCGR1Aq,
CCR7Q, FCGR1Bq
IL-8 Signaling Females 2.48 3.90 0.063 8 IL8q, GNG11q, JUNq, RHOBq, DEFA1q, VEGFBQ, HBEGFq, PTGS2q,
IRAK3q, ITGB5q, MMP9q, GNG7Q
Males 0.62 1.44 0.031 26 IL8q, JUNq, RHOBq, HBEGFq, PTGS2q, GNG7Q
ILK Signaling Females 2.07 3.34 0.060 11 MYCQ, FLNBQ, JUNq, RHOBq, VEGFBQ, LEF1Q, HIF1Aq, PTGS2q,
CREB5q, ITGB5q, MMP9q
Males 0.62 1.46 0.032 25 MYCQ, JUNq, RHOBq, LEF1Q, HIF1Aq, PTGS2q
Oncostatin M Signaling Females 1.47 2.50 0.118 21 MT2Aq, IL6STQ, OSMq, STAT1q
Males 1.45 2.98 0.118 6 MT2Aq, IL6STQ, OSMq, STAT1q
OX40 Signaling Pathway Females 1.70 2.77 0.082 19 HLA-DOAQ, JUNq, HLA-DQA1q, HLA-DOBQ, TRAF5Q
Males 1.11 2.42 0.066 9 HLA-DOAQ, JUNq, HLA-DOBQ, TRAF5Q
PI3K Signaling in B Lymphocytes Females 2.64 4.11 0.078 7 BLKQ, PTPRCq, CD19Q, IL4RQ, JUNq, ATF3q, CD79BQ, PLCG1Q,
PIK3AP1q, CD79AQ
Males 1.45 2.89 0.055 7 BLKQ, PTPRCq, CD19Q, JUNq, ATF3q, CD79BQ, CD79AQ
Role of JAK family kinases in IL-6-
type Cytokine Signaling
Females 1.87 3.01 0.154 16 IL6STQ, SOCS3q, OSMq, STAT1q
Males 1.84 3.51 0.154 3 IL6STQ, SOCS3q, OSMq, STAT1q
Role of NFAT in Regulation of the
Immune Response
Females 3.48 5.14 0.070 5 HLA-DOAQ, CD79BQ, FCGR2Aq, HLA-DQA1q, PLCG1Q, FCGR1Aq,
GNG7Q, CD79AQ, GNG11q, JUNq, CD86q, HLA-DOBQ, FCGR1Bq
Males 1.45 2.84 0.043 8 HLA-DOAQ, JUNq, CD79BQ, HLA-DOBQ, FCGR1Aq, GNG7Q, CD79AQ,
FCGR1Bq
T Helper Cell Differentiation Females 4.00 5.80 0.130 3 IL6STQ, IL4RQ, HLA-DOAQ, HLA-DQA1q, CD86q, HLA-DOBQ, CXCR5Q,
STAT1q, BCL6q
Males 1.93 3.76 0.087 2 IL6STQ, HLA-DOAQ, HLA-DOBQ, CXCR5Q, STAT1q, BCL6q
TREM1 Signaling Females 2.70 4.25 0.123 6 IL8q, TLR10Q, PLCG1Q, CD86q, IL1Bq, CD83q, CCL3q
Males 1.01 2.21 0.070 12 IL8q, TLR10Q, IL1Bq, CD83q
P-values were derived from Fisher’s exact test, -log(0.05) = 1.3, and the Benjamini-Hochberg-corrected t-test (FDR), –log(0.25) = 0.61. The ratio is the number of
differentially expressed genes in the data set divided by the total number of genes in the given pathway. The rank indicates the position of the pathway in the gender-
specific pathway list. A complete list of the pathways affected in both genders is shown in supplementary Table S3.
doi:10.1371/journal.pone.0066229.t002
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levels of estrogen and androgens decrease in aging males and low
levels of estrogen are associated with a risk of fracture. However,
the relative contribution of estrogens versus androgens in aging
males is unclear [16]. PDGF signaling, which was also affected in
males, has also been shown to be affected by a lack of estrogen
[22].
The study presented here has some limitations. We have shown
that the proportions of different T cell subpopulations or the
proportion of monocyte-macrophage lineage cells do not differ
between the genders (Table S4). However, there may be
differences in the proportion of other cell populations that may
explain some of the observed differences in gene expression.
Table 3. The canonical pathways that were affected in nonagenarian females.
Canonical pathways 2logFDR 2logP Ratio Molecules
Prostanoid Biosynthesis 2.07 3.34 0.333 PTGS1q, PTGS2q, PTGDSq
CTLA4 Signaling in Cytotoxic T Lymphocytes 1.90 3.06 0.074 HLA-DOAQ, HLA-DQA1q, TRAT1Q, PLCG1Q, CD86q, HLA-DOBQ, CTLA4q
CCR5 Signaling in Macrophages 1.90 3.06 0.074 GNG11q, JUNq, PLCG1Q, CCL3q, GNG7Q, FASq
IL-15 Production 1.77 2.88 0.138 TXKQ, IL15q, STAT1q, IRF1q
IL-10 Signaling 1.76 2.85 0.083 IL1R2q, SOCS3q, IL4RQ, JUNq, FCGR2Aq, IL1Bq
p38 MAPK Signaling 1.36 2.33 0.060 IL1R2q, MYCQ, IL1Bq, IRAK3q, CREB5q, STAT1q, FASq
P2Y Purigenic Receptor Signaling Pathway 1.30 2.25 0.056 MYCQ, ITGA2Bq, GNG11q, JUNq, PLCG1Q, CREB5q, GNG7Q
iNOS Signaling 1.26 2.17 0.087 JUNq, IRAK3q, STAT1q, IRF1q
Cytotoxic T Lymphocyte-mediated Apoptosis of
Target Cells
1.24 2.13 0.077 HLA-DOAQ, HLA-DQA1q, HLA-DOBQ, FASq
Differential Regulation of Cytokine Production in
Intestinal Epithelial Cells by IL-17A and IL-17F
1.23 2.10 0.130 LCN2q, IL1Bq, CCL3q
iCOS-iCOSL Signaling in T Helper Cells 1.21 2.06 0.054 PTPRCq, HLA-DOAQ, HLA-DQA1q, TRAT1Q, PLCG1Q, HLA-DOBQ
IL-4 Signaling 1.19 2.04 0.067 IL4RQ, HLA-DOAQ, HLA-DQA1q, HLA-DOBQ, FCER2Q
Nur77 Signaling in T Lymphocytes 1.19 2.03 0.070 HLA-DOAQ, HLA-DQA1q, CD86q, HLA-DOBQ
PKCh Signaling in T Lymphocytes 1.06 1.87 0.047 HLA-DOAQ, JUNq, HLA-DQA1q, PLCG1Q, CD86q, HLA-DOBQ
TNFR2 Signaling 1.06 1.86 0.094 JUNq, LTAQ, TNFAIP3q
Calcium-induced T Lymphocyte Apoptosis 1.02 1.82 0.066 HLA-DOAQ, HLA-DQA1q, PLCG1Q, HLA-DOBQ
G Protein Signaling Mediated by Tubby 0.97 1.74 0.081 GNG11q, PLCG1Q, GNG7Q
Glucocorticoid Receptor Signaling 0.97 1.74 0.036 IL1R2q, IL8q, JUNq, SGK1q, CDKN1Aq, IL1Bq, PTGS2q, STAT1q,CCL3q,
FCGR1Aq
Inhibition of Angiogenesis by TSP1 0.93 1.67 0.091 JUNq, THBS1q, MMP9q
Role of JAK1 and JAK3 in cc Cytokine Signaling 0.91 1.64 0.064 SOCS3q, IL4RQ, IL15q, STAT1q
ERK5 Signaling 0.87 1.59 0.063 IL6STQ, MYCQ, SGK1q, CREB5q
Antigen Presentation Pathway 0.86 1.57 0.075 HLA-DOAQ, HLA-DQA1q, HLA-DOBQ
Production of Nitric Oxide and Reactive Oxygen
Species in Macrophages
0.68 1.35 0.038 JUNq, RHOBq, PLCG1Q, PCYOX1q, STAT1q, SPI1q, IRF1q
Phospholipase C Signaling 0.66 1.33 0.033 GNG11q, CD79BQ, RHOBq, FCGR2Aq, PLCG1Q, CREB5q, GNG7Q,
CD79AQ
The pathways that were significant only in females are shown. The p-values were derived from Fisher’s exact test, 2log(0.05) = 1.3 and the Benjamini-Hochberg-
corrected t-test (FDR), 2log(0.25) = 0.61. The ratio is the number of differentially expressed genes in the data set divided by the total number of genes in the given
pathway.
doi:10.1371/journal.pone.0066229.t003
Table 4. The canonical pathways that were affected in nonagenarian males.
Canonical pathways 2logFDR 2logP Ratio Molecules
Estrogen-mediated S-phase Entry 1.11 2.41 0.111 MYCQ, CDKN1Aq, E2F5Q
PDGF Signaling 0.77 1.71 0.051 MYCQ, JUNq, STAT1q, PDGFRBq
CD27 Signaling in Lymphocytes 0.62 1.52 0.055 JUNq, TRAF5Q, CD27Q
PPAR Signaling 0.62 1.49 0.040 JUNq, IL1Bq, PTGS2q, PDGFRBq
Role of Pattern Recognition Receptors in Recognition
of Bacteria and Viruses
0.62 1.48 0.042 NLRP3q, C5AR1q, IL1Bq, OAS3q
The pathways that were significant only in males are shown. The p-values were derived from Fisher’s exact test, 2log(0.05) = 1.3 and the Benjamini-Hochberg-corrected
t-test (FDR), 2log(0.25) = 0.61. The ratio is the number of differentially expressed genes in the data set divided by the total number of genes in the given pathway.
doi:10.1371/journal.pone.0066229.t004
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The number of healthy young controls used is relatively small in
comparison to nonagenarian group. Thus, the small sample size
will have an effect on the power of statistical testing to identify
differentially expressed genes. To address this limitation, we have
used statistical test specifically designed for small sample sizes.
Data interpretation through pathway enrichment also mitigates
this limitation as we do not need to observe all, only a significant
fraction of genes belonging to a given pathway.
Additionally, we have previously shown that aging-related
changes are affected by the CMV serostatus [23]. Because of the
high seroprevalence of CMV in the nonagenarian study popula-
tion (96% of females and 95% of males are seropositive for CMV),
we cannot assess the combinatorial effect of gender and CMV on
the age-associated changes in transcription.
This study focused on the effect of aging on the immune systems
of males and females. It has been known for decades that gender
has an influence on the function of the immune system, with
females generally having a stronger immune response. Gender
differences in the immune response are also detectable at
transcriptomic levels [24]. Sex steroids, estrogen and testosterone,
clearly play a role in driving gender differences in the immune
response. Presently, there is no biological explanation for these
aging-induced differences, and we can only speculate based on the
available evidence. For example, aging strongly influences the
levels of sex steroids, but during menopause estrogen levels
decrease more rapidly than testosterone levels do during
andropause [16]. Specifically, the positive effects of estrogens on
the immune system stop at about age 45–55.
Another interesting possibility involves potential changes in the
X-chromosome. The X-chromosome contains the largest number
of immune-related genes in the genome [25], and aging may
modify the function of genes on the X-chromosome. In females,
X-chromosome is inactivated at random during an early
embryonic stage (i.e. there is a 50/50 ratio of the maternal and
paternal X-chromosomes). However, in elderly individuals, this
ratio may be skewed. During a 13-year follow-up it was recently
shown that this skewing is associated with survival [26]. It remains
to be established whether this skewing has an influence on the
expression of immune-related genes.
Materials and Methods
Ethics Statement
All participants in this study provided their written, informed
consent. This study was conducted according to the principles
expressed in the declaration of Helsinki, and the study protocol
was approved by the ethics committee of the city of Tampere
(Study protocol number SOTE 1592/402/96).
Population
The study population consisted of 146 nonagenarians (females
n = 103, males n= 43) who were participating in the Vitality 90+
study, and 30 young, healthy controls (aged 19–30 years, median
22.5 years; females n= 21, males n = 9). All of the study subjects
were of Western European descent. The Vitality 90+ study is an
ongoing prospective population-based study that includes both
home-dwelling and institutionalized individuals aged 90 years or
more who live in the city of Tampere, Finland. The recruitment
and characterization of the participants were performed as
previously reported for earlier Vitality 90+ study cohorts [27]. In
this study, we included only individuals born in 1920, and the
samples used in this study were collected in the year 2010. The
nonagenarians included in the study had not had any infections or
received any vaccinations in the 30 days prior to the blood sample
collection. The young controls consisted of healthy laboratory
personnel who did not have any medically diagnosed chronic
illnesses, who were non-smokers and who had not had any
infections or received any vaccinations within the two weeks prior
to the blood sample collection.
Sample Collection
The blood samples were collected into EDTA-containing tubes
by a trained medical student during a home visit. All of the blood
samples were drawn between 8 am and 12 am. The samples were
directly subjected to leucocyte separation with a Ficoll-Paque
density gradient (Ficoll-PaqueTM Premium, cat.no. 17-5442-03,
GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The PBMC
layer was collected and a subset of cells was suspended in 150 ml of
RNAlater solution (Ambion Inc., Austin, TX, USA) for use in a
microarray analysis. The cells that were to be used for FACS
analysis were suspended in 1 ml of a Freezing solution (5/8 FBS,
2/8 RPMI-160 medium, 1/8 DMSO) (FBS cat. no. F7524,
Sigma-Aldrich, MO, USA; RPMI: cat. no. R0883, Sigma-Aldrich,
MO, USA; DMSO: cat. no. 1.02931.0500, VWR, Espoo, Fin-
land).
RNA Extraction and Transcriptomic Analysis
For RNA extraction, equal amounts of PBS and RNAlater were
added to the cell suspension and then removed by centrifugation,
leaving only the cell pellet. RNA was purified using an miRNeasy
mini kit (Qiagen, CA, USA) according to the manufacturer’s
protocol using on-column DNase digestion (AppliChem GmbH,
Darmstadt, Germany). The concentration and quality of the RNA
were assessed with an Agilent RNA 6000 Nano Kit on Agilent
2100 Bioanalyzer (Agilent Technologies, CA, USA).
Labeled cRNA was prepared from 330 ng of total RNA using
an Illumina TotalPrep RNA Amplification Kit (Ambion Inc., TX,
USA) with overnight incubation according to the manufacturer’s
protocol. The quality of the labeled cRNA was determined using a
2100 Bioanalyzer (Agilent Technologies). In total, 1,500 ng of
labeled cRNA was hybridized to a HumanHT-12 v4 Expression
BeadChip (Cat no. BD-103-0204, Illumina Inc., CA, USA)
overnight according to the Illumina protocol in the Core Facility
at the Department of Biotechnology, University of Tartu. The
chips were scanned using a Beadscan (Illumina Inc.). The
microarray data are available in the GEO database (http://
www.ncbi.nlm.nih.gov/geo/), accession number GSE40366.
Data Preprocessing and Statistical Analysis
The preprocessing, filtering and analysis of the data were
performed with the Chipster v2.3 program [8] (CSC, Espoo,
Finland). The lumi pipeline was used for data preprocessing and
normalization [28]. The Array_Address_ID was used as a probe
identifier, background correction was performed with the
bgAdjust.affy package, and the data were transformed with the
vst (variance stabilizing transformation) method and normalized
with the rsn (robust spline normalization) method. The vst and rsn
methods were chosen, because they are recommended in the
literature and are designed to take in to account the technical
replicates in each Illumina chip (the bead array technology) [28],
[29], [30]. The quality control was performed by using box blot,
density blot and PCA analysis.
To filter out the non-expressed probes and probes whose
expression did not change between study groups, we filtered the
data based on the coefficient of variation (CV, standard deviation/
mean). We included the 5% of probes (2367) with the highest CV,
i.e., the highest variation between nonagenarian and control
samples. The nonagenarian samples and control samples were
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compared with an empirical Bayes two-group test from the limma
package [31] using the Benjamini-Hochberg false discovery rate
(FDR) for multiple testing correction. The threshold for signifi-
cance for p-values was set to 0.05. From these genes, we classified
those with a linear fold change above 1.5 or below -1.5 as
differentially expressed. This classification was performed to
obtain comparable groups of genes from both genders. Because
more females were included in the study, performing the analysis
without a fold change limit produced almost three times more
genes for the females compared with the males.
IPA
To identify canonical pathways associated with aging, we
analyzed the gene sets with IPA software (IngenuityH Systems,
www.ingenuity.com). According to the manufacturer, the canon-
ical pathways are well-characterized metabolic and cell signaling
pathways that have been curated and hand-drawn by PhD-level
scientists. The information used to construct the canonical
pathways is derived from specific journal articles, review articles,
text books, and the KEGG Ligand database. The canonical
pathways are directional. All of the data sources provided by the
Ingenuity Knowledge Base were included in the IPA analysis. For
the association of molecules, only experimentally observed results
were accepted and only human data were considered. The
HumanHT-12 v 4.0 was used as a reference set to generate p-
values for the pathways, and Fisher’s exact test and Benjamini-
Hochberg multiple testing correction (FDR) were used to calculate
p-values for the pathways. With these parameters, we obtained
293 and 213 analysis-ready molecules for females and males,
respectively, out of a total of 339 and 248 genes that were
differentially expressed. We considered a canonical pathway to be
significantly affected at p,0.05 (-logP.1.3), at FDR,0.25 and
when the pathway contained a minimum of 3 genes. Pathways
associated with cancer and other disease, as defined by Ingenuity
SystemsH, were excluded from the analysis. The IPA analysis was
performed on 6.3.2013.
qPCR Verification
In total, 300 ng of RNA was converted to cDNA using a High
Capacity cDNA Reverse Transcription Kit (Part No. 4368814,
Applied Biosystems, CA, USA). Because the amount of cDNA was
limited, we performed a pre-amplification step using TaqManH
PreAmp Master Mix (Part No. 4348266, Applied Biosystems).
This protocol amplifies small amounts of cDNA without intro-
ducing bias to the sample. In brief, 15 ng of cDNA was amplified
for 10 cycles according to the manufacturer’s instructions using the
same assays with which the actual qPCRs were performed (CD83
Hs01077168_g1, IL8 Hs00174103_m1, LRRN3 Hs00539582_s1,
PLCG1 Hs01008225_m1 and GUSB Hs00939627_m1 as endog-
enous control). GUSB was selected as the control gene because
GUSB was shown to be the most stable transcript in gene
expression studies that used aging PBMCs [32]. The pre-amplified
product was diluted 1:5 with TE- buffer.
Transcript levels were determined with the single gene assays
described above, using TaqManH Gene Expression Master Mix
(Part No. 4369016, Applied Biosystems). To determine whether
the transcripts were differentially expressed between the nonage-
narians and the young controls, we calculated the RQ values with
RQ Manager Software (Applied Biosystems).
FACS
The proportions of different lymphocyte populations were
determined using FACS analysis (BD FACSCanto II) and the
results were analyzed with BD FACS Diva, version 6.1.3 (BD
Biosciences, Franklin Lakes, NJ, USA). The antibodies used were
FITC-CD14 (cat. no. 11-0149), PerCP-Cy5.5-CD3 (45-0037),
APC-CD28 (17-0289) (eBioscience, San Diego, CA, USA), PE-
CyTM7-CD4 (cat. no. 557852) and APC-CyTM7-CD8 (557834)
(BD Biosciences).
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